Literature DB >> 11355018

The peroxin Pex6p gene is impaired in peroxisomal biogenesis disorders of complementation group 6.

N Matsumoto1, S Tamura, A Moser, H W Moser, N Braverman, Y Suzuki, N Shimozawa, N Kondo, Y Fujiki.   

Abstract

Human genetic peroxisomal biogenesis disorders (PBDs), such as Zellweger syndrome, comprise 13 different complementation groups (CGs). Eleven peroxin genes, termed PEXs, responsible for PBDs have been identified, whereas pathogenic genes for PBDs of 2CGs, CG-A (the same CG as CG8 in the United States and Europe) and CG6, remained unidentified. We herein provide several lines of novel evidence indicating that PEX6, the pathogenic gene for CG4, is impaired in PBD of CG6. Expression of PEX6 restored peroxisome assembly in fibroblasts from a CG6 PBD patient. This patient was a compound heterozygote for PEX6 gene alleles. Accordingly, by merging CG6 with CG4, human PBDs are now classified into 12CGs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11355018     DOI: 10.1007/s100380170078

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  10 in total

1.  A novel mutation in the PEX12 gene causing a peroxisomal biogenesis disorder.

Authors:  Jana Konkoľová; Robert Petrovič; Ján Chandoga; Edita Halasová; Petra Jungová; Daniel Böhmer
Journal:  Mol Biol Rep       Date:  2015-06-21       Impact factor: 2.316

2.  Shuttling mechanism of peroxisome targeting signal type 1 receptor Pex5: ATP-independent import and ATP-dependent export.

Authors:  Non Miyata; Yukio Fujiki
Journal:  Mol Cell Biol       Date:  2005-12       Impact factor: 4.272

3.  A PEX6-defective peroxisomal biogenesis disorder with severe phenotype in an infant, versus mild phenotype resembling Usher syndrome in the affected parents.

Authors:  Annick Raas-Rothschild; Ronald J A Wanders; Petra A W Mooijer; Jeannette Gootjes; Hans R Waterham; Alisa Gutman; Yasuyuki Suzuki; Nobuyuki Shimozawa; Naomi Kondo; Gideon Eshel; Marc Espeel; Frank Roels; Stanley H Korman
Journal:  Am J Hum Genet       Date:  2002-02-28       Impact factor: 11.025

4.  Mutations in novel peroxin gene PEX26 that cause peroxisome-biogenesis disorders of complementation group 8 provide a genotype-phenotype correlation.

Authors:  Naomi Matsumoto; Shigehiko Tamura; Satomi Furuki; Non Miyata; Ann Moser; Nobuyuki Shimozawa; Hugo W Moser; Yasuyuki Suzuki; Naomi Kondo; Yukio Fujiki
Journal:  Am J Hum Genet       Date:  2003-07-08       Impact factor: 11.025

5.  A founder mutation in the PEX6 gene is responsible for increased incidence of Zellweger syndrome in a French Canadian population.

Authors:  Sebastien Levesque; Charles Morin; Simon-Pierre Guay; Josee Villeneuve; Pascale Marquis; Wing Yan Yik; Sarn Jiralerspong; Luigi Bouchard; Steven Steinberg; Joseph G Hacia; Ken Dewar; Nancy E Braverman
Journal:  BMC Med Genet       Date:  2012-08-15       Impact factor: 2.103

Review 6.  Peroxisomes in brain development and function.

Authors:  Johannes Berger; Fabian Dorninger; Sonja Forss-Petter; Markus Kunze
Journal:  Biochim Biophys Acta       Date:  2015-12-11

7.  Strong cis-acting expression quantitative trait loci for the genes encoding SNHG5 and PEX6.

Authors:  Jihyeon Lee; Jihye Ryu; Chaeyoung Lee
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

Review 8.  Peroxisome biogenesis in mammalian cells.

Authors:  Yukio Fujiki; Kanji Okumoto; Satoru Mukai; Masanori Honsho; Shigehiko Tamura
Journal:  Front Physiol       Date:  2014-08-15       Impact factor: 4.566

Review 9.  Peroxisome biogenesis and human peroxisome-deficiency disorders.

Authors:  Yukio Fujiki
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2016       Impact factor: 3.493

Review 10.  Genetic burden linked to founder effects in Saguenay-Lac-Saint-Jean illustrates the importance of genetic screening test availability.

Authors:  Mbarka Bchetnia; Luigi Bouchard; Jean Mathieu; Philippe M Campeau; Charles Morin; Diane Brisson; Anne-Marie Laberge; Hélène Vézina; Daniel Gaudet; Catherine Laprise
Journal:  J Med Genet       Date:  2021-04-28       Impact factor: 6.318

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.